CANLI
Yükleniyor Veriler getiriliyor…
SCI JCR Q1 Özgün Makale Scopus
Development of an Antiviral Ion-Activated In Situ Gel Containing 18β-Glycyrrhetinic Acid: A Promising Alternative against Respiratory Syncytial Virus
PHARMACEUTICS 2023 Cilt 15 Sayı 8
Scopus Eşleşmesi Bulundu
8
Atıf
15
Cilt
🔓
Açık Erişim
Özet
The human respiratory syncytial virus (hRSV) is a major cause of serious lower respiratory infections and poses a considerable risk to public health globally. Only a few treatments are currently used to treat RSV infections, and there is no RSV vaccination. Therefore, the need for clinically applicable, affordable, and safe RSV prevention and treatment solutions is urgent. In this study, an ion-activated in situ gelling formulation containing the broad-spectrum antiviral 18β-glycyrrhetinic acid (GA) was developed for its antiviral effect on RSV. In this context, pH, mechanical characteristics, ex vivo mucoadhesive strength, in vitro drug release pattern, sprayability, drug content, and stability were all examined. Rheological characteristics were also tested using in vitro gelation capacity and rheological synergism tests. Finally, the cytotoxic and antiviral activities of the optimized in situ gelling formulation on RSV cultured in the human laryngeal epidermoid carcinoma (HEp-2) cell line were evaluated. In conclusion, the optimized formulation prepared with a combination of 0.5% w/w gellan gum and 0.5% w/w sodium carboxymethylcellulose demonstrated good gelation capacity and sprayability (weight deviation between the first day of the experiment (T0) and the last day of the experiment (T14) was 0.34%), desired rheological synergism (mucoadhesive force (Fb): 9.53 Pa), mechanical characteristics (adhesiveness: 0.300 ± 0.05 mJ), ex vivo bioadhesion force (19.67 ± 1.90 g), drug content uniformity (RSD%: 0.494), and sustained drug release over a period of 6 h (24.56% ± 0.49). The optimized formulation demonstrated strong anti-hRSV activity (simultaneous half maximal effective concentration (EC50) = 0.05 µg/mL; selectivity index (SI) = 306; pre-infection EC50 = 0.154 µg/mL; SI = 100), which was significantly higher than that of ribavirin (EC50 = 4.189 µg/mL; SI = 28) used as a positive control against hRSV, according to the results of the antiviral activity test. In conclusion, this study showed that nasal in situ gelling spray can prevent viral infection and replication by directly inhibiting viral entry or modulating viral replication.
Web of Science Eşleşmesi Bulundu
6
WoS Atıf
15
Cilt
Article
Belge Türü
Kaynak: PHARMACEUTICS
Anahtar Kelimeler (WoS)

Havuzumuzdaki Atıflar 0

Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 8.

Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi Bilgisi Otomatik ISSN Eşleştirmesi 2023 yılı verileri
Pharmaceutics
Q1
SJR Quartile
0,892
SJR Skoru
129
H-Index
🔓
Açık Erişim
Kategoriler: Pharmaceutical Science (Q1)
Alanlar: Pharmacology, Toxicology and Pharmaceutics
Ülke: Switzerland · Multidisciplinary Digital Publishing Institute (MDPI)
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir. Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.

Makale Bilgileri

Dergi PHARMACEUTICS
ISSN 1999-4923
Yıl 2023 / 1. ay
Cilt / Sayı 15 / 8
Makale Türü Özgün Makale
Hakemlik Hakemli
Endeks SCI
JCR Quartile Q1
Teşvik Puanı 3,00 · YÖKSİS Akademik Teşvik
Yayın Dili Türkçe
Kapsam Uluslararası
Toplam Yazar 6 kişi
Erişim Türü Elektronik
Alan Fen Bilimleri ve Matematik Temel Alanı Biyoloji Viroloji in situ gelling formulations, intranasal delivery, gellan gum, mucoadhesion, 18 beta-glycyrrhetinic acid, respiratory syncytial virus, common cold, antiviral activity

YÖKSİS Yazar Kaydı

Yazar Adı Özkan Burcu, ALTUNTAŞ EBRU, ÜNLÜ ÜMMÜHAN, DOĞAN HASAN HÜSEYİN, Özsoy Yıldız, Çakır Koç Rabia
YÖKSİS ID 7779294

Metrikler

Scopus Atıf 8
Havuz Atıfları 0
JCR Quartile Q1
Teşvik Puanı 3,00
Yazar Sayısı 6